JW Pharma announced on the 6th that Phase III clinical trials that proved the effects and safety of patients with type hemophilia have been published in the online edition of the Lancet Hematology 2023, an international journal. Hemlibra is a type A hemophilia disease caused by the deficiency of factor XIII. It is the only anti-antibody patient and non-antibody patient with resistance to the existing therapeutic agent (8-factor formulations), and the prevention effect persists with subcutaneous injections for up to 4 weeks. Type A hemophilia is divided into mildness (more than 5% to less than 5% to less than 40%), moderate (1% or more to 5% or less), and severe (less than 1%) according to the figures of factor XIII